Norovirus has been linked to twelve outbreaks on cruise ships in 2025, sickening nearly 1,500 people, according to CDC data.

On January 8, 2025, Cocrystal Pharma, Inc. (NASDAQ:COCP) announced results from the Phase 1 trial of CDI-988 for the prophylaxis and treatment of norovirus, coronavirus, and other viral infections.

An increasing number of studies show that immunosuppressive therapy is a risk factor for norovirus infections. Noroviruses are highly resistant to harsh environmental conditions, and the ...

17 strains Company reported favorable safety and tolerability of CDI-988 in Phase 1 and plans to initiate a human challenge study in 2025 for the treatment and prevention of norovirus infection ...

Of these instances, nine were caused by norovirus.Staying healthy on boardCruise passengers who present stomach bug symptoms can help limit the spread of infection by “promptly reporting their ...